跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

RAB0555

Sigma-Aldrich

人 PLAU/尿激酶型纤溶酶原激活剂 ELISA 试剂盒

for serum, plasma, cell culture supernatants and urine

别名:

PLAU ELISA Kit, Urokinase Detection Kit

登录查看公司和协议定价
所有图片(1)

About This Item

分類程式碼代碼:
41116158
NACRES:
NA.32

物種活性

human

包裝

kit of 96 wells (12 strips x 8 wells)

技術

ELISA: suitable

輸入

sample type urine
sample type plasma
sample type serum
sample type cell culture supernatant(s)

assay range

inter-assay cv: <10%
intra-assay cv: <12%
sensitivity: 10 pg/mL

檢測方法

colorimetric

運輸包裝

wet ice

儲存溫度

−20°C

基因資訊

human ... PLAU (5328)

相关类别

一般說明

The antibody pair provided in this kit detects Human uPA in serum, plasma, cell culture supernatants, and urine.

應用

请参考Protocol了解详情。

其他說明

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

试剂盒组分也可单独购买

产品编号
说明
化学品安全说明书
  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)化学品安全说明书
  • RABSTOP3ELISA Stop Solution (Item I)化学品安全说明书
  • RABELADAELISA 1X Assay/Sample Diluent Buffer A (Item D1)化学品安全说明书
  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)化学品安全说明书
  • RABWASH420X Wash Buffer (Item B)化学品安全说明书

象形圖

Corrosion
GHS05

訊號詞

Warning

危險聲明

H290

防範說明

P234 - P390

危險分類

Met. Corr. 1

儲存類別代碼

8A - Combustible corrosive hazardous materials

閃點（°F）

Not applicable

閃點（°C）

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0404K0374
0302K0374
0410K0374
1122J0374
1030F0374

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Hongwei Zhou et al.
Oncology letters, 14(5), 5189-5196 (2017-11-09)
The overexpression of the oncogene human epidermal growth factor receptor 2 (HER-2) has been associated with decreased disease-free survival and is a marker of poor prognosis of invasive breast cancer. Although the high efficacy of trastuzumab, a drug that targets
C Ostheimer et al.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 194(6), 539-551 (2018-01-18)
The urokinase plasminogen activator system (uPA, uPAR, PAI‑1) is upregulated in cancer and high plasma levels are associated with poor prognosis. Their interaction with hypoxia-related osteopontin (OPN) which is also overexpressed in malignant tumors suggests potential clinical relevance. However, the
Tomasz W Kaminski et al.
International urology and nephrology, 50(1), 127-135 (2017-10-24)
Chronic kidney disease (CKD) is an estimated risk factor for increased mortality and morbidity due to fibrinolytic system disturbances. Progressive loss of renal function leads to retention of uremic toxins. Anthranilic acid (AA) is a tryptophan-derived uremic toxin with multidirectional
Lutz Beckert et al.
JCI insight, 5 (2019-04-19)
Current dosing of intrapleural fibrinolytic therapy (IPFT) in adults with complicated parapneumonic effusion (CPE) / empyema is empiric, as dose-escalation trials have not previously been conducted. We hypothesized that LTI-01 (scuPA), which is relatively resistant to PA inhibitor-1 (PAI-1), would
Anastasia Gabrielyan et al.
Stem cell research & therapy, 8(1), 212-212 (2017-10-04)
The main goal of bone tissue engineering has been the generation of healthy bone in order to replace affected tissue. Therefore, optimized biomaterials are needed which allow the survival and growth of mesenchymal stem cells. Until now the key challenge
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门